326 related articles for article (PubMed ID: 31455411)
1. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.
Zhou ZQ; Zhao JJ; Pan QZ; Chen CL; Liu Y; Tang Y; Zhu Q; Weng DS; Xia JC
J Immunother Cancer; 2019 Aug; 7(1):228. PubMed ID: 31455411
[TBL] [Abstract][Full Text] [Related]
2. High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.
Chang B; Shen L; Wang K; Jin J; Huang T; Chen Q; Li W; Wu P
Liver Int; 2018 Aug; 38(8):1449-1458. PubMed ID: 29356308
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
Chen CL; Pan QZ; Zhao JJ; Wang Y; Li YQ; Wang QJ; Pan K; Weng DS; Jiang SS; Tang Y; Zhang XF; Zhang HX; Zhou ZQ; Zeng YX; Xia JC
Oncoimmunology; 2016 Jul; 5(7):e1176653. PubMed ID: 27622026
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.
Pan K; Li YQ; Wang W; Xu L; Zhang YJ; Zheng HX; Zhao JJ; Qiu HJ; Weng DS; Li JJ; Wang QJ; Huang LX; He J; Chen SP; Ke ML; Wu PH; Chen MS; Li SP; Xia JC; Zeng YX
Ann Surg Oncol; 2013 Dec; 20(13):4305-11. PubMed ID: 23892527
[TBL] [Abstract][Full Text] [Related]
6. 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer.
Lin M; Liang S; Jiang F; Xu J; Zhu W; Qian W; Hu Y; Zhou Z; Chen J; Niu L; Xu K; Lv Y
Immunol Lett; 2017 Mar; 183():37-43. PubMed ID: 28143792
[TBL] [Abstract][Full Text] [Related]
7. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma.
Pan QZ; Liu Q; Zhou YQ; Zhao JJ; Wang QJ; Li YQ; Tang Y; Gu JM; He J; Chen SP; Weng DS; Xia JC
Cancer Immunol Immunother; 2020 May; 69(5):825-834. PubMed ID: 32060687
[TBL] [Abstract][Full Text] [Related]
8. Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment.
Xie Y; Huang L; Chen L; Lin X; Chen L; Zheng Q
World J Surg Oncol; 2017 Nov; 15(1):209. PubMed ID: 29179719
[TBL] [Abstract][Full Text] [Related]
9. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences.
Ren J; Di L; Song G; Yu J; Jia J; Zhu Y; Yan Y; Jiang H; Liang X; Che L; Zhang J; Wan F; Wang X; Zhou X; Lyerly HK
Clin Transl Oncol; 2013 Oct; 15(10):780-8. PubMed ID: 23359185
[TBL] [Abstract][Full Text] [Related]
10. Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer.
Li Y; Wang C; Xu M; Kong C; Qu A; Zhang M; Zheng Z; Zhang G
J Cancer Res Clin Oncol; 2017 May; 143(5):861-871. PubMed ID: 28108815
[TBL] [Abstract][Full Text] [Related]
11. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
[TBL] [Abstract][Full Text] [Related]
12. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the Clinical Efficacy of Dendritic Cell -cytokine Induced Killer Cell-based Adoptive Immunotherapy for Colorectal Cancer.
Xu H; Qin W; Feng H; Song D; Yang X; Zhang J
Immunol Invest; 2021 Aug; 50(6):622-633. PubMed ID: 32718264
[No Abstract] [Full Text] [Related]
14. Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy.
Li J; Chen L; Xiong Y; Zheng X; Xie Q; Zhou Q; Shi L; Wu C; Jiang J; Wang H
Cell Physiol Biochem; 2017; 41(3):907-920. PubMed ID: 28222426
[TBL] [Abstract][Full Text] [Related]
15. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
Guo H; Ding Q; Gong Y; Gilcrease MZ; Zhao M; Zhao J; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Breast Cancer Res; 2020 Jun; 22(1):69. PubMed ID: 32576238
[TBL] [Abstract][Full Text] [Related]
16. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
Du Q; Che J; Jiang X; Li L; Luo X; Li Q
Clin Breast Cancer; 2020 Feb; 20(1):e99-e111. PubMed ID: 31521537
[TBL] [Abstract][Full Text] [Related]
18. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection.
Pan QZ; Zhao JJ; Yang CP; Zhou YQ; Lin JZ; Tang Y; Gu JM; Wang QJ; Li YQ; He J; Chen SP; Song MJ; Huang Y; Yang JY; Weng DS; Xia JC
Oncoimmunology; 2020; 9(1):1752563. PubMed ID: 32363125
[TBL] [Abstract][Full Text] [Related]
20. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
